Using the recombinant PFFs [55] and human A53T α-syn models [126], both of which drive α-synucleinopathies in mice, treatment with anti-LAG-3 antibodies or LAG-3−/− knockout resulted in reduced pathology [55, 126]. The gene discussed is LAG3; the disease is synucleinopathy.